Related Experiment Videos
[Recent perspectives second-line chemotherapy for breast cancer]
Nobuko Fujiuchi1, Katsuhiko Ohokubo, Toshiaki Saeki
1Dept. of Breast Oncology, Saitama Medical School, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 29, 2005
Summary
This review discusses chemotherapy for metastatic breast cancer, shifting from CMF to anthracyclines and taxanes. Treatment sequencing depends on prior anthracycline and taxane exposure for recurrent disease.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Review of recent advancements in breast cancer chemotherapy.
- Shift in treatment paradigms from traditional CMF to anthracycline and taxane-based regimens.
Purpose of the Study:
- To review the development of chemotherapeutic agents for breast cancer.
- To guide the sequence of chemotherapy for metastatic breast cancer based on prior treatment.
Main Methods:
- Literature review of chemotherapeutic agents and treatment strategies.
- Analysis of treatment sequencing for recurrent and metastatic breast cancer.
Main Results:
- Anthracycline regimens are recommended for patients not previously treated with them.
- Taxanes with or without capecitabine are indicated for patients who received prior anthracyclines.
- Capecitabine monotherapy is suggested for patients who received both anthracyclines and taxanes.
Conclusions:
- Treatment decisions for metastatic breast cancer should be individualized based on prior chemotherapy exposure.
- Chemotherapy sequencing is crucial for optimizing outcomes in recurrent breast cancer.
- Physicians should select the most appropriate chemotherapeutic agent based on patient-specific factors.